Brief: Aligos Therapeutics Inc Announces IND Clearance For Nash Lead, Alg-055009
21/09/2023 12:32
Sept 21 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS INC - ALIGOS THERAPEUTICS ANNOUNCES
IND
CLEARANCE FOR NASH LEAD, ALG-055009
* ALIGOS THERAPEUTICS INC - REMAIN ON TRACK TO SUBMIT PHASE
2A
PROTOCOL TO IND IN Q4 2023 AND EXPECT TO INITIATE ENROLLMENT IN
Q1 2024
* ALIGOS THERAPEUTICS INC - EXPECT TO SHARE TOPLINE PROOF OF
CONCEPT DATA FROM STUDY IN Q4 2024
Source text for Eikon: ID:nGNXCFXZZ
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue